Definitive fractionated re-irradiation for local recurrence following stereotactic body radiotherapy for primary lung cancer

Tadamasa Yoshitake, Yoshiyuki Shioyama, Katsumasa Nakamura, Tomonari Sasaki, Saiji Ohga, Makoto Shinoto, Kotaro Terashima, Kaori Asai, Keiji Matsumoto, Hideki Hirata, Hiroshi Honda

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Aim: To retrospectively evaluate the efficacy and safety of definitive fractionated re-irradiation for local recurrence following stereotactic body radiotherapy (SBRT) for primary lung cancer. Patients and Methods: Between April 2003 and December 2011, 398 patients with primary lung tumor underwent SBRT at the Kyushu University Hospital, and 46 out of these developed local recurrence after SBRT. Definitive fractionated re-irradiation was performed for 17 out of the 46 patients. The median dose of reirradiation was 60 Gy/ 30 fractions. Concurrent chemotherapy was given to four patients. Results: The median follow-up duration was 12.6 months. At one year post-reirradiation, local progression-free survival was 33.8%; progression-free survival, 30.9%; cause-specific survival, 79.3%; and overall survival, 74.7%. No severe adverse events were observed during the follow-up. Conclusion: Definitive fractionated re-irradiation is thought to be a safe alternative therapy for local recurrence following SBRT, although its efficacy may be not entirely satisfactory.

Original languageEnglish
Pages (from-to)5649-5654
Number of pages6
JournalAnticancer research
Volume33
Issue number12
Publication statusPublished - Dec 1 2013

Fingerprint

Radiosurgery
Lung Neoplasms
Recurrence
Disease-Free Survival
Survival
Complementary Therapies
Re-Irradiation
Safety
Drug Therapy
Lung
Neoplasms

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Definitive fractionated re-irradiation for local recurrence following stereotactic body radiotherapy for primary lung cancer. / Yoshitake, Tadamasa; Shioyama, Yoshiyuki; Nakamura, Katsumasa; Sasaki, Tomonari; Ohga, Saiji; Shinoto, Makoto; Terashima, Kotaro; Asai, Kaori; Matsumoto, Keiji; Hirata, Hideki; Honda, Hiroshi.

In: Anticancer research, Vol. 33, No. 12, 01.12.2013, p. 5649-5654.

Research output: Contribution to journalArticle

Yoshitake, Tadamasa ; Shioyama, Yoshiyuki ; Nakamura, Katsumasa ; Sasaki, Tomonari ; Ohga, Saiji ; Shinoto, Makoto ; Terashima, Kotaro ; Asai, Kaori ; Matsumoto, Keiji ; Hirata, Hideki ; Honda, Hiroshi. / Definitive fractionated re-irradiation for local recurrence following stereotactic body radiotherapy for primary lung cancer. In: Anticancer research. 2013 ; Vol. 33, No. 12. pp. 5649-5654.
@article{204b276a3b8044e09107c42042240123,
title = "Definitive fractionated re-irradiation for local recurrence following stereotactic body radiotherapy for primary lung cancer",
abstract = "Aim: To retrospectively evaluate the efficacy and safety of definitive fractionated re-irradiation for local recurrence following stereotactic body radiotherapy (SBRT) for primary lung cancer. Patients and Methods: Between April 2003 and December 2011, 398 patients with primary lung tumor underwent SBRT at the Kyushu University Hospital, and 46 out of these developed local recurrence after SBRT. Definitive fractionated re-irradiation was performed for 17 out of the 46 patients. The median dose of reirradiation was 60 Gy/ 30 fractions. Concurrent chemotherapy was given to four patients. Results: The median follow-up duration was 12.6 months. At one year post-reirradiation, local progression-free survival was 33.8{\%}; progression-free survival, 30.9{\%}; cause-specific survival, 79.3{\%}; and overall survival, 74.7{\%}. No severe adverse events were observed during the follow-up. Conclusion: Definitive fractionated re-irradiation is thought to be a safe alternative therapy for local recurrence following SBRT, although its efficacy may be not entirely satisfactory.",
author = "Tadamasa Yoshitake and Yoshiyuki Shioyama and Katsumasa Nakamura and Tomonari Sasaki and Saiji Ohga and Makoto Shinoto and Kotaro Terashima and Kaori Asai and Keiji Matsumoto and Hideki Hirata and Hiroshi Honda",
year = "2013",
month = "12",
day = "1",
language = "English",
volume = "33",
pages = "5649--5654",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "12",

}

TY - JOUR

T1 - Definitive fractionated re-irradiation for local recurrence following stereotactic body radiotherapy for primary lung cancer

AU - Yoshitake, Tadamasa

AU - Shioyama, Yoshiyuki

AU - Nakamura, Katsumasa

AU - Sasaki, Tomonari

AU - Ohga, Saiji

AU - Shinoto, Makoto

AU - Terashima, Kotaro

AU - Asai, Kaori

AU - Matsumoto, Keiji

AU - Hirata, Hideki

AU - Honda, Hiroshi

PY - 2013/12/1

Y1 - 2013/12/1

N2 - Aim: To retrospectively evaluate the efficacy and safety of definitive fractionated re-irradiation for local recurrence following stereotactic body radiotherapy (SBRT) for primary lung cancer. Patients and Methods: Between April 2003 and December 2011, 398 patients with primary lung tumor underwent SBRT at the Kyushu University Hospital, and 46 out of these developed local recurrence after SBRT. Definitive fractionated re-irradiation was performed for 17 out of the 46 patients. The median dose of reirradiation was 60 Gy/ 30 fractions. Concurrent chemotherapy was given to four patients. Results: The median follow-up duration was 12.6 months. At one year post-reirradiation, local progression-free survival was 33.8%; progression-free survival, 30.9%; cause-specific survival, 79.3%; and overall survival, 74.7%. No severe adverse events were observed during the follow-up. Conclusion: Definitive fractionated re-irradiation is thought to be a safe alternative therapy for local recurrence following SBRT, although its efficacy may be not entirely satisfactory.

AB - Aim: To retrospectively evaluate the efficacy and safety of definitive fractionated re-irradiation for local recurrence following stereotactic body radiotherapy (SBRT) for primary lung cancer. Patients and Methods: Between April 2003 and December 2011, 398 patients with primary lung tumor underwent SBRT at the Kyushu University Hospital, and 46 out of these developed local recurrence after SBRT. Definitive fractionated re-irradiation was performed for 17 out of the 46 patients. The median dose of reirradiation was 60 Gy/ 30 fractions. Concurrent chemotherapy was given to four patients. Results: The median follow-up duration was 12.6 months. At one year post-reirradiation, local progression-free survival was 33.8%; progression-free survival, 30.9%; cause-specific survival, 79.3%; and overall survival, 74.7%. No severe adverse events were observed during the follow-up. Conclusion: Definitive fractionated re-irradiation is thought to be a safe alternative therapy for local recurrence following SBRT, although its efficacy may be not entirely satisfactory.

UR - http://www.scopus.com/inward/record.url?scp=84891387161&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84891387161&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84891387161

VL - 33

SP - 5649

EP - 5654

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 12

ER -